Descrizione del progetto
Development of the first oral treatment for mild-to-moderate psoriasis
According to the World Health Organisation, there is an urgent demand for an efficient and safe psoriasis drug that could be used without necessitating a close monitoring of the patient. Available drugs do not have satisfactory efficacy and often cause serious side effects. The EU-funded PsoraxPlan project aims to develop and deliver Psorax35 as an efficient drug for mild and moderate cases of psoriasis. If Psorax35 proves efficient against psoriasis, it could also have a positive effect on comorbidities such as arthritis and cardiovascular complications. The objective for the first phase of the whole project is to deliver a comprehensive feasibility analysis of this drug for the treatment of mild-to-moderate psoriasis.
Invito a presentare proposte
Vedi altri progetti per questo bando